News

Public · Published

Wedbush maintains Ultragenyx Pharmaceutical at Neutral, lowers price target to $22 from $25

Wedbush kept its Neutral rating on Ultragenyx Pharmaceutical and cut its price target to $22 from $25, a 12.0% decrease. The revised target implies 32.3% upside from the November 3 closing price of $16.63.

Published:

Updated:

What happened

Wedbush kept its Neutral rating on Ultragenyx Pharmaceutical and cut its price target to $22 from $25, a 12.0% decrease. The revised target implies 32.3% upside from the November 3 closing price of $16.63.

Confirmed

Global impact / market context

The lower target signals Wedbush sees less value than before, while retaining its Neutral view. A price target is an analyst’s estimate, not a promised share price; investors may weigh the change when judging expected gains against the company’s risks.

Analyst inference

The article reports one broker’s view, not a change in Ultragenyx’s reported business results or a company announcement. Its stated 32.3% upside is measured against the November 3 close, so it describes the target’s comparison with that past price, not a forecasted return.

Analyst inference

What to watch

  1. Check whether Wedbush publishes further changes to its Neutral rating or $22 target; the article does not say whether additional revisions are planned. Analyst inference
  2. Compare any later analyst targets with the November 3 closing price of $16.63, since the reported 32.3% implied upside uses that specific reference point. Analyst inference
  3. Look for company updates on results or business plans; this article gives no operating data explaining why Wedbush lowered its target. Analyst inference

Evidence

  • Original source link unavailable